Health & Environment
Study Highlights Potential for Rare-Disease Drug Manufacturing and Accessibility in India
The Hindu56m
THE BRIEF
1
India accounts for 1,004 reported rare genetic disorders, with cumulative annual treatment costs for crowdfunding patients exceeding ₹9,000 crore.
2
International orphan drug legislation like the U.S. Orphan Drug Act successfully boosted approved therapies from 38 to 1,122 by providing tax incentives and market exclusivity.
3
Experts suggest streamlining regulatory pathways, offering financial incentives, and utilizing government procurement to build a competitive rare-disease pharmaceutical sector in India.